EMERYVILLE, Calif.–(BUSINESS WIRE)–$NBY #Avenova–NovaBay Pharmaceuticals report financial results for the second quarter of 2018.
Author: Business Wire
Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2018 and provided a business update. “We are encouraged with our progress through the first half of 2018,” said Antony Mattessich, President and Chief Executive Officer. “The on-time resubmission a
Cataract Therapeutics | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#DrugPipeline–Technavio has published a new report on the drug development pipeline for cataract therapeutics, including a detailed study of the pipeline molecules.
EyeQue Hires Chief Marketing Officer to Strengthen Leadership Team for Accelerated Company Growth
NEWARK, Calif.–(BUSINESS WIRE)–#seebeyond–EyeQue adds industry veteran Datta Nadkarni as CMO to lead next revolution of eye care– at-home vision testing.
Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its second quarter 2018 financial results will be released before the market opens on Tuesday, August 14, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
SAN DIEGO & MELBOURNE, Australia–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America. ACADIA plans to initiate a Phase 3 randomized, double-blind pl
Kedalion Therapeutics Closes $5 Million Series A Financing Round
MENLO PARK, Calif.–(BUSINESS WIRE)–Kedalion Therapeutics Closes $5 Million Series A Financing Round
Company Profile for RadianceTx
–(BUSINESS WIRE)–RadianceTx is a trademark of Radiance Therapeutics, Inc., a Delaware corporation. Radiance Therapeutics, Inc., a leader in ophthalmic therapeutic innovation, is commercializing a clinically demonstrated novel anti-metabolite therapy for glaucoma drainage surgery. For more information, visit: www.radiancetherapeutics.com. Company: RadianceTx Headquarters Address: 7440 N. Oracle Road, Bldg. 1 Tucson, AZ 85704 Main Telephone: Info@RadianceTx.com Website: http://www.radia
Eye Health America Acquires Montgomery & Riddle Eyecare and The Surgery and Laser Center at Professional Park, A Leading Eye Care Provider in South Carolina
ATLANTA–(BUSINESS WIRE)–Eye Health America (EHA), a leader in eye care practice management, today announced its acquisition of Montgomery & Riddle Eyecare and The Surgery & Laser Center at Professional Park, a prominent eye care provider in South Carolina. The acquisition of Montgomery & Riddle Eyecare strengthens Eye Health America’s presence in the region and establishes a strategic partnership between Montgomery & Riddle Eyecare and EHA’s additional member practices in Sout
Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes. Omeros managemen…
Glaukos Corporation Announces Second Quarter 2018 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the second quarter ended June 30, 2018 and recent corporate accomplishments. “BioTime’s execution in the second quarter demonstrates the strength of our strategy. Our focus on clinical progress has accelerated our product development of our core programs. With our non-core programs, we have, in fewer than two years, g
Leber’s Hereditary Optic Neuropathy | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#LHON–Technavio has published a new report on the drug development pipeline for Leber’s hereditary optic neuropathy (LHON).
Global Ocular Implants Market Analysis, Trends & Forecasts 2018-2022, With an Expected CAGR of 12.52% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ocular Implants Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The analysts forecast the global ocular implants market to grow at a CAGR of 12.52% during the period 2018-2022. Ocular i…
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the distribution ratio for the distribution of AgeX Therapeutics shares owned by BioTime on a pro-rata basis to eligible BioTime shareholders. BioTime shareholders as of the record date will be entitled to receive one share of AgeX common stock for every 10 shares of BioTime common stock held. BioTime s
Lions Eye Institute and RTI Donor Services Expand Strategic Relationship to Maximize the Gift of Tissue Donation
TAMPA, Fla.–(BUSINESS WIRE)–The Lions Eye Institute for Transplant and Research (LEITR), a nonprofit organization dedicated to the recovery, evaluation and distribution of eye tissue, and RTI Donor Services, Inc. (RTIDS), a nonprofit organization dedicated to providing responsible stewardship of the gift of tissue donation, announced an expanded relationship to increase efficiencies in tissue donation and enhance patients’ lives. Through this relationship, each partner will focus on its core
STAAR Surgical ICL Sales Up 67%; Company Raises Outlook for 2018
MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended Jun…
Global Keratometers Market 2018-2022| Growth Potential in Emerging Economies to Propel Demand| Technavio
LONDON–(BUSINESS WIRE)–#Healthcare–The global keratometers market 2018-2022 is expected to post a CAGR of close to 4% during the forecast period, according to Technavio.